Emerging studies suggest this peptide, a dual agonist targeting both the gut-brain axis and glucose-dependent insulinotropic polypeptide , appears to offer a promising advancement for body loss . Early human trials have shown substantial decreases in abdominal fat , possibly surpassing other obesity medications . Despite this, more assessment is ne